Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis

Immunomodulatory therapy that combines ulinastatin and Tα1 significantly improves all-cause mortality, inflammatory mediators and duration of mechanical ventilation in subjects with sepsis.